CCCC

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted protein degradation therapies. Headquartered in Watertown, Massachusetts, C4 Therapeutics is advancing a pipeline of novel small molecule drugs designed to degrade disease-causing proteins rather than simply inhibiting their function. The company's proprietary TORPEDO platform enables the rational design of oral degrader drugs that harness the body's natural protein recycling machinery to selectively eliminate specific proteins implicated in cancer and other diseases. C4 Therapeutics focuses primarily on oncology indications where protein degradation may offer advantages over traditional therapeutic approaches. The company's clinical pipeline includes multiple degrader candidates targeting validated oncology targets, with programs in various stages of clinical development. C4 Therapeutics collaborates with pharmaceutical partners to advance certain programs while maintaining full ownership of others. The company represents part of the emerging targeted protein degradation field, which has attracted significant scientific and investor interest as a potentially transformative therapeutic modality. C4 Therapeutics continues to invest heavily in research and development to advance its pipeline and expand its degrader platform.